23.9 C
New York
Thursday, June 18, 2026

Tag: arm

newssourceFORcompanyinformationcontent1marketreleases

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

Trump’s Fiscal Fireworks: A Brilliant Plan for Economic Chaos

Ah, Washington. The paragon of fiscal prudence. For decades, our esteemed lawmakers have been engaged in a bipartisan race to see who can degrade...

BitMart Research—Reframing the On-Chain Narrative: What New Story Is Base Telling?

Mahe, Seychelles, July 01, 2025 (GLOBE NEWSWIRE) -- BitMart Research, the research arm of BitMart Exchange, has released a comprehensive analysis on the resurgence of the Base ecosystem, highlighting its explosive growth, evolving narratives, and rising institutional alignment. As daily active addresses, TVL, and transaction volumes reach new highs, Base is rapidly transitioning from a speculative L2 to a foundational layer for compliant, on-chain financial and content infrastructure. With support from Coinbase’s strategic initiatives and breakout projects like Virtual and Kaito redefining launch dynamics and the attention economy, Base is emerging as a pivotal force in bridging traditional finance and Web3 innovation.

The Gabriel Love Foundation, Philanthropic Arm of Gabriel & Co. Announces the GIA Gabriel Love Foundation Scholarship in Memory of the late Elias Gabriel

NEW YORK, July 1, 2025 /PRNewswire/ -- Gabriel & Co., the most trusted leader and award winning brand of the bridal and fashion fine jewelry...

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)...

“Path of Liberty: That Which Unites US” Honors Veterans on July 4th as the Nation Begins the Countdown to America’s 250th Birthday

Path of Liberty will offer active, off-duty, and retired military members and their families special  complimentary tickets for prime viewing. NEW YORK, June 30, 2025...

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...

The Cigna Group Foundation Announces Grants to 24 Nonprofits, Builds on Momentum to Help Address Youth Mental Health Crisis

BLOOMFIELD, Conn., June 30, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today announced its second...

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line...

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

StarKist®, Feed the Children, and Feed 479 Unite to Support 400 Northwest Arkansas Families with Food and Resources

Community Resource Rally Delivers Essential Aid to Local Families Facing Summer Insecurity ROGERS, Ark., June 27, 2025 /PRNewswire/ -- With summer in full swing and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsArm

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers